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Succinate is an intermediate of the citric acid cycle, which is generated in mitochondria following hydrolytic release of CoA from succinyl‐CoA. Succinate can accumulate in mitochondria and gets exported to the extracellular milieu when there is an imbalance between nutrients and/or oxygen and energy demands [1](#all13005-bib-0001){ref-type="ref"}. Extracellular succinate binds to its specific receptor, SUCNR1/GPR91 [2](#all13005-bib-0002){ref-type="ref"}, on the plasma membrane of hepatic, renal, retinal and immune cells, instructing them to secrete hormones, growth factors or cytokines involved in multiple normal and pathologic processes [3](#all13005-bib-0003){ref-type="ref"}. There is evidence indicating that triggering GPR91 prevents premature subretinal age‐related macular degeneration‐like lesions [4](#all13005-bib-0004){ref-type="ref"} and facilitates the recovery from cerebral hypoxic--ischemic events [5](#all13005-bib-0005){ref-type="ref"}. On the other hand, the sensory function of GPR91 detecting succinate following ischemic stress has been implicated in the mechanisms governing diabetic retinopathy [6](#all13005-bib-0006){ref-type="ref"}, [7](#all13005-bib-0007){ref-type="ref"}, causing cardiac hypertrophy [8](#all13005-bib-0008){ref-type="ref"}, [9](#all13005-bib-0009){ref-type="ref"} and eliciting hepatic stellate cell activation [10](#all13005-bib-0010){ref-type="ref"} and hepatic fibrosis [11](#all13005-bib-0011){ref-type="ref"}. In addition to hypoxia, elevated glucose levels, as observed in diabetes, also result in the export of succinate to the extracellular environment [12](#all13005-bib-0012){ref-type="ref"}, [13](#all13005-bib-0013){ref-type="ref"}. In this case, increased interstitial levels of succinate are also sensed by GPR91 in the kidney juxtaglomerular apparatus [14](#all13005-bib-0014){ref-type="ref"} and macula densa cells [15](#all13005-bib-0015){ref-type="ref"}, causing the release of renin, which ultimately lead to hypertension and renal tissue injury [13](#all13005-bib-0013){ref-type="ref"}. Furthermore, our laboratory has previously shown that succinate can be released as a consequence of necrosis following tissue damage. We demonstrated that immature dendritic cells (DC) express GPR91 and utilize this receptor to sense immunologic danger and to enhance antigen‐presenting functions required for optimal T‐cell activation [16](#all13005-bib-0016){ref-type="ref"}. We hypothesized that GPR91 plays a broader role in immune regulation, and we therefore aimed to examine its pathophysiologic or protective role in the context of allergic and inflammatory challenges.

Methods {#all13005-sec-0006}
=======

Animals {#all13005-sec-0007}
-------

*Sucnr1*‐deficient (*Sucnr1* ^*−/−*^) mice were generated as previously described [16](#all13005-bib-0016){ref-type="ref"}. The original model was generated in the C57BL/6N background. These mice featured the single‐nucleotide deletion in the *Crb1* gene reported by Mattapallil et al. [17](#all13005-bib-0017){ref-type="ref"}, which is present in all C57BL/6N substrains and can lead to ocular phenotypes. Thus, *Sucnr1* ^*−/−*^ mice were backcrossed (\>10 generations) onto the C57BL/6J background (Janvier Labs, Le Genest‐Saint‐Isle, France), which does not carry this mutation. The immune phenotype and functions of the *Sucnr1* ^*−/−*^ mice on C57BL/6N and C57BL/6J backgrounds were equivalent. Furthermore, the immune phenotype of *Sucnr1* ^*−/−*^ mice was normal and comparable to that of wild‐type (wt) mice (Fig. S1). All experiments were performed using 8‐ to 16‐week‐old mice. All animal studies described in this report were performed according to Swiss animal protection laws issued by the Cantonal Veterinary Office Basel‐Stadt, Switzerland, by the Austrian Animal Experimentation Law and by the Novartis Animal Welfare Policy.

Animal models {#all13005-sec-0008}
-------------

Allergic and inflammatory responses were conducted in parallel on wt and *Sucnr1* ^*−/−*^ mice. Elicitation and sensitization for allergic contact dermatitis (ACD) was performed with 1% oxazolone (Sigma‐Aldrich, Buchs, Switzerland) in acetone as previously described [18](#all13005-bib-0018){ref-type="ref"}. RNA was extracted from ear tissue and subjected to real‐time RT‐PCR analysis for mouse EF‐1α, IL‐1β, IL‐4, IL‐5, IL‐13, IL‐17, IFN‐γ and TNF‐α. Irritant contact dermatitis (ICD) was induced by a single topical application of 10 μl of 0.005% 12‐O‐tetradecanoylphorbol‐13‐acetate (TPA) (wt/vol in acetone; Sigma‐Aldrich) on the inner and outer surfaces of the left ears of wt and *Sucnr1* ^*−/−*^ mice. The right ears were treated with vehicle alone (acetone). After 6 h, animals were euthanized and right and left ears were removed. Treatment‐induced swelling was calculated as percentage increase in ear weight as described by Sheu et al. [19](#all13005-bib-0019){ref-type="ref"}. Passive cutaneous anaphylaxis (PCA) tests, using PBS or 50 ng IgE (anti‐DNP antibody; BD Biosciences, Allschwil, Switzerland) and subsequent (48 h) *i.v*. injection with 100 μg DNP‐BSA (Sigma‐Aldrich, Buchs, Switzerland) diluted in 0.5% Evans blue (in 0.9% NaCl; AppliChem, Darmstadt, Germany), were conducted as described elsewhere [20](#all13005-bib-0020){ref-type="ref"}. The ovalbumin (OVA)‐induced allergic asthma model was performed as described by Mojtabavi et al. [21](#all13005-bib-0021){ref-type="ref"}. Briefly, wt and *Sucnr1* ^*−/−*^ mice were sensitized *i.p*. on day 0 with PBS or 10 μg OVA (A550; Sigma) and were boosted *i.p*. after 21 days. On day 28 and 29, mice were challenged twice a day with either 1% PBS aerosol or 1% OVA aerosol for 1 h. On day 31, mice were killed and bronchoalveolar lavage (BAL) was performed using 2 ml of PBS. Cytospins were made, and slides were fixed with methanol for 5 min. After staining with May--Grünwald--Giemsa solution (Merck, Zug, Switzerland), cellularity of neutrophils, eosinophils, lymphocytes and macrophages in the BAL was analyzed using a hemacytometer. IgE and IgG concentrations were analyzed from BAL and serum by standard sandwich ELISA using specific antibodies (BD Biosciences). Antigen‐induced arthritis (AIA) using methylated bovine serum albumin (mBSA) and K/BxN serum transfer‐induced arthritis were conducted as described previously [22](#all13005-bib-0022){ref-type="ref"}.

Real‐time RT‐PCR {#all13005-sec-0009}
----------------

Total cellular RNA was extracted from cells using RNeasy Mini Kit (Qiagen, Hilden, Germany) according to manufacturer\'s instructions. Real‐time RT‐PCR was performed on an ABI7500 Thermocycler using Platinum ThermoScript One‐Step system (Invitrogen, Zug, Switzerland). All mouse gene‐specific mRNA levels were determined using commercial TaqMan GeneAssays (Applied Biosystems, Zug, Switzerland): *Eif1a* (Mm00456651_m1), *Sucnr1* (Mm00519024_m1), *Tnf* (Mm00443258_m1), *Il1b* (Mm00434228_m1), *Il4* (Mm00445259_m1), *Il5* (Mm01290072_g1), *Il13* (Mm00434206_g1), *Il17* (Mm00521423_m1) and *Ifng* (Mm99999071_m1). For measurement of human *EF1A* mRNA, primers and probes (Eurogentec, Liege, Belgium) were designed with [primerexpress]{.smallcaps} software (Applied Biosystems, Zug, Switzerland) (forward, 5′‐TTTGAGACCAGCAAGTACTATGTGACT‐3′; reverse 5′‐TCAGCCTGAGATGTCCCTGTAA‐3′; probe 5′‐TCATTGATGCCCCAGGACACAGAGAC‐3′). The expression of gene‐specific human *SUCNR1* mRNA was measured with commercial TaqMan GeneAssays kits (Applied Biosystems, Hs00263701_m1).

Mass cytometry by time of flight {#all13005-sec-0010}
--------------------------------

Mass cytometry by time of flight (CyTOF) analysis on spleens, inguinal lymph nodes, blood and bone marrow of wt and *Sucnr1* ^*−/−*^ mice was performed as previously described [23](#all13005-bib-0023){ref-type="ref"} using a cocktail of monoclonal antibodies, conjugated to monoisotopic lanthanides (Table S1). All samples (three wt and three *Sucnr1* ^*−/−*^) isolated from a given tissue were barcoded using the Cell‐ID 20‐Plex Pd Barcoding Kit (Fluidigm, SanFrancisco, CA, USA), and acquired simultaneously as a mixture to correct for fluctuations in signal strength during acquisition time. Data analysis was performed using [cytobank]{.smallcaps} (Mountain View, CA, USA), [spotfire]{.smallcaps} (Palo Alto, CA, USA) software and R‐based algorithms.

Human cell isolation and differentiation {#all13005-sec-0011}
----------------------------------------

Peripheral blood mononuclear cells were isolated using standard Ficoll density gradients from peripheral blood of healthy volunteers obtained from the Swiss Red Cross after signing informed consent. Human mast cells were differentiated from hematopoietic precursors (Lonza, Switzerland) as described by Rådinger et al. [24](#all13005-bib-0024){ref-type="ref"}.

Generation and activation of mouse bone marrow‐derived mast cells {#all13005-sec-0012}
-----------------------------------------------------------------

Bone marrow (BM) cells were obtained by flushing the humeri, femurs and tibias of wt and *Sucnr1* ^*−/−*^ mice with HBSS (Gibco, Zug, Switzerland) and subsequently cultured for 4--8 weeks using RPMI‐1640/glutaMAX medium supplemented with 10% FCS, 1% penicillin/streptomycin, 1% MEM essential amino acids, 50 μM β‐ME, 1 mM sodium pyruvate (all from Gibco) and 20 ng/ml IL‐3 (Novartis, Basel, Switzerland). To investigate the role of GPR91 on mast cell development, BM cells were cultured in X‐Vivo 15 medium (Gibco) supplemented with 1% MEM essential amino acids, 50 μM β‐ME, 1 mM sodium pyruvate and 20 ng/ml IL‐3 in the presence or absence of 50 μM succinate. After 4 weeks of cultivation, BM‐derived mast cells (BMMC) were analyzed by flow cytometry using CD11b and CD117 antibodies (BD Biosciences). The purity of the BMMC was always \>98%. BMMC were generally stimulated for 1--4 h in 96‐well flat‐bottom plates at a density of 2 × 10^5^ cells/well using supplemented RPMI‐1640/glutaMAX medium and 2 μg/ml IgE (BD Biosciences) and 0.1 μg/ml DNP‐BSA as antigen (Sigma) in the absence or presence of succinate. At indicated time points, cells were harvested and processed for mRNA expression using cytokine‐specific primers and probes (as described above). To monitor mast cell degranulation by the measurement of the release of the granule component, β‐hexosaminidase, BMMC were washed with RPMI‐1640/glutaMAX (without phenol red) supplemented with 25 mM HEPES, 0.1% BSA, 1% penicillin/streptomycin, 1× sodium pyruvate, 1× MEM essential amino acids and 50 μM β‐mercaptoethanol and cross‐linked for 1 h with 2 μg/ml IgE and 0.1 μg/ml DNP‐BSA as the antigen. Cells were centrifuged, and supernatants were incubated for 30 min with a substrate 4‐methylumbelliferyl‐*N*‐acetyl‐β‐[d]{.smallcaps}‐glucosaminide (Sigma‐Aldrich) diluted in citrate buffer and measured using white OptiPlate (PerkinElmer, Schwarzenbach, Switzerland). In some cases, BMMC were transfected using specific siRNA against random or mouse *Sucnr1* (Ambion, Zug, Switzerland, s96542, s96541, s96543) gene for 24 h. Cells were then stimulated with either vehicle or 2 μg/ml IgE and 0.1 μg/ml DNP‐BSA as antigen for 1 h before RNA was isolated and *Sucnr1* and *Tnf* mRNA expression were amplified by RT‐PCR.

Statistics {#all13005-sec-0013}
----------

One‐tailed Mann--Whitney *U*‐test or two‐tailed Student\'s *t*‐test was used to analyze results. Significant differences with *P* \< 0.05, *P* \< 0.01 and *P* \< 0.001 are illustrated as \*, \*\* and \*\*\*, respectively.

Results and discussion {#all13005-sec-0014}
======================

The skin is an effective barrier used by all vertebrates as an interface with the environment to provide the first line of defense from external factors. Infectious agents, toxins or trauma can harm the skin, causing the necrotic secretion of internal cell metabolites, which contribute to the activation of DC and the initiation of immune responses [25](#all13005-bib-0025){ref-type="ref"}. In this context, we aimed to test the hypothesis that GPR91 expressed on epidermal Langerhans and dermal DC potentiates the development of ACD by sensing succinate release following tissue damage in the skin. We compared the reactions of wt and *Sucnr1* ^*−/−*^ mice to a classical ACD challenge (i.e. using oxazolone as the inducing hapten and measuring ear thickness as the primary readout). We hypothesized that hypersensitive responses to oxazolone would be lowest in *Sucnr1* ^*−/−*^ mice. Surprisingly, the extent of the responses observed in *Sucnr1* ^*−/−*^ mice following oxazolone challenge was consistently higher than that displayed by the wt counterparts (Fig. [1](#all13005-fig-0001){ref-type="fig"}A,B). This result was confounding, as we had postulated earlier that antagonizing GPR91 would be beneficial for the treatment of several immune disorders [16](#all13005-bib-0016){ref-type="ref"} and such a reaction could compromise the safety of putative GPR91‐based therapeutics. On the other hand, skin hyperreactivity was not augmented during the sensitization procedure with oxazolone and was reduced, rather than enhanced, following an ICD challenge (Fig. S2) of naïve *Sucnr1* ^*−/−*^ mice with TPA. Furthermore, the strong hypersensitivity of *Sucnr1* ^*−/−*^ mice to oxazolone did not correlate with an underlying increased T‐cell response, either measured as T‐cell infiltration (not shown) or measured as cutaneous transcript expression for classical Th2 cytokines like IL‐4 and IL‐13, which were rather reduced in the challenged gene‐deficient mice (Fig. [1](#all13005-fig-0001){ref-type="fig"}C). Of note, mRNA expression for the innate inflammatory cytokines IL‐1β and TNF‐α was not elevated in the ears of challenged *Sucnr1* ^*−/−*^ mouse group (Fig. S3A), which also did not display signs for exacerbated Th1, Th2 or Th17 cell differentiation, as assessed by the transcript expression of signature cytokines in the ear draining lymph nodes (Fig. S3B).

![*Sucnr1* ^*−/−*^ mice display exacerbated mast cell responses *in vitro* and *in vivo*. (A) Representative hematoxylin staining of ear sections from wt and *Sucnr1* ^*−/−*^ mice after oxazolone challenge. (B) Comparative ear thickness from eight wt and eight *Sucnr1* ^*−/−*^ oxazolone‐challenged mice. (C) Cytokine mRNA expression in oxazolone‐challenged ears from eight wt and eight *Sucnr1* ^*−/−*^ mice. (D) *Sucnr1* mRNA expression from bone marrow (BM) cells and BM‐derived mast cells isolated from two and eight, respectively, different mice. (E) TNF‐α mRNA expression by BM‐derived mast cells from wt and *Sucnr1* ^*−/−*^ mice stimulated for indicated period of time with 2 μg/ml IgE plus 0.1 μg/ml DNP‐BSA. Boxplots represent fold increases in TNF‐α mRNA by stimulated mast cells related to corresponding unstimulated controls (pooled data from three independent experiments). (F) Evans Blue extravasation after passive cutaneous anaphylaxis (PCA) of five wt and five *Sucnr1* ^*−/−*^ mice. Analysis using one‐tailed Mann--Whitney *U*‐test.](ALL-72-444-g001){#all13005-fig-0001}

A closer look at the hematoxylin staining presented in Fig. [1](#all13005-fig-0001){ref-type="fig"}A revealed a severe intradermal and subcutaneous edema in the ears of the hapten‐challenged *Sucnr1* ^*−/−*^ mice, which is indicative for mast cell degranulation. RT‐PCR analysis of both mouse and human mast cells differentiated *in vitro* from corresponding bone marrow precursors revealed copious transcripts encoding GPR91 (Figs [1](#all13005-fig-0001){ref-type="fig"}D and S4). These observations prompted us to compare the *in vitro* activation of mast cells differentiated from the bone marrow of wt and *Sucnr1* ^*−/−*^ mice. As shown in Fig. [1](#all13005-fig-0001){ref-type="fig"}E, mast cells from both, wt and *Sucnr1* ^*−/−*^ mice, express TNF‐α mRNA, following *in vitro* activation with IgE cross‐linked by a specific antigen. TNF‐α expression was maximal at 1 h after activation and decreased progressively in the subsequent 4 h. However, at all time points examined, the magnitude of the response displayed by the mast cells derived from the *Sucnr1* ^*−/−*^ mice was higher than that observed from wt counterparts. To further assess the *in vivo* biological relevance of the enhanced activation displayed by *Sucnr1* ^*−/−*^ mast cells*,* we monitored blood vessel permeability following a PCA test. As demonstrated in Figs [1](#all13005-fig-0001){ref-type="fig"}F and S5, *Sucnr1* ^*−/−*^ mice displayed exacerbated blood vessel leakage, as shown by the release of the Evans blue following cross‐link of *i.d*. injected DNP‐specific IgE by the specific hapten. The responses were specific, as they were not elicited at the dermal sites injected with PBS (Fig. S5). On the other hand, the PCA test is an artificial setting that simply recapitulates the mechanistic mast cell activation induced *in vitro*, and thus, the potential risk for allergic hypersensitization associated with *Sucnr1* deficiency was further assessed using an OVA‐specific sensitization and challenge procedure, which mimics the allergic response associated with asthma. The macrophages present in the BAL of OVA‐aerosol‐challenged mice were less abundant in the *Sucnr1* ^*−/−*^ mouse group (Fig. [2](#all13005-fig-0002){ref-type="fig"}A). Lymphocytes, neutrophils and eosinophils, as well as overall cell counts, in the BAL of OVA‐aerosol‐challenged *Sucnr1* ^*−/−*^ mice were always reduced with respect to BAL from wt mice (Fig. [2](#all13005-fig-0002){ref-type="fig"}A,B), even though the results did not reach statistical significance. By contrast, the BAL levels of IgE (Fig. [2](#all13005-fig-0002){ref-type="fig"}C), but not IgG (not shown), were significantly reduced in the *Sucnr1* ^*−/−*^ group. Concordantly, serum IgE but not IgG was also reduced in *Sucnr1* ^*−/−*^ mice (not shown). These results are in agreement with our previous report [16](#all13005-bib-0016){ref-type="ref"} implicating succinate as an endogenous adjuvant for T‐cell‐mediated responses.

![*Sucnr1* ^*−/−*^ mice do not have increase cellularity in bronchoalveolar lavage (BAL) and mount limited IgE responses after challenge with aerosolized ovalbumin (OVA). (A) Macrophage, lymphocyte, neutrophil and eosinophil infiltration in BAL of four wt and five *Sucnr1* ^*−/−*^ mice upon sensitization and challenge with OVA. (B) Total cell counts of BAL described in A. (C) IgE in BAL of mice challenged with OVA as described in A. Data were analyzed using one‐tailed Mann--Whitney *U*‐test.](ALL-72-444-g002){#all13005-fig-0002}

The above data indicate that the absence of GPR91 signaling during the sensitization phase of immediate type I hypersensitivity responses reduces the development of T‐cell‐dependent IgE production and thus minimizes the risk of anaphylaxis upon subsequent encounter with the allergen. However, these experiments will not predict the risk of exacerbated mast cell activation mediated by GPR91 antagonists in an environment where preexisting immunocomplexes can drive pathology. Furthermore, bronchial hyperreactivity is not necessarily driven by mast cells in the C57BL/6 background, particularly if the challenge procedure is not repeated over a lengthy period of time [26](#all13005-bib-0026){ref-type="ref"}. Thus, elucidating the threat of anaphylaxis would require specific and bioavailable low molecular weight antagonists of GPR91, which, to the best of our knowledge, are not yet available. We envisioned an alternative experimental condition in the mouse arthritis model induced by the transfer of the autoantibodies, directed to glucose‐6‐phosphatase isomerase, that develop in K/BxN mice [27](#all13005-bib-0027){ref-type="ref"}. Passive transfer of serum from K/BxN mice to healthy wt recipient induces arthritis without the need to involve the generation of an adaptive response [27](#all13005-bib-0027){ref-type="ref"}. The mechanism of this pathogenic antibody‐induced disease has been investigated in detail, revealing major roles for IL‐1β, TNF‐α [28](#all13005-bib-0028){ref-type="ref"}, FcγRIII/CD16 [29](#all13005-bib-0029){ref-type="ref"}, [30](#all13005-bib-0030){ref-type="ref"} and C5aR/CD88 [29](#all13005-bib-0029){ref-type="ref"}. In addition, the observation that mice with functional mast cell deficiency are protected from K/BxN serum induced arthritis and that disease susceptibility is restored in these mice following reconstitution with normal mast cells has been used as a strong argument implicating mast cells in this pathologic process [30](#all13005-bib-0030){ref-type="ref"}, [31](#all13005-bib-0031){ref-type="ref"}. Thus, we anticipated that if the lack of *Sucnr1* predisposes for exacerbated mast cell function, the arthritic disease induced by pathogenic autoreactive antibodies derived from the serum of K/BxN mice should manifest more intensely in *Sucnr1* ^*−/−*^ mice than in wt counterparts. Concomitantly, arthritis induced by immunization with methylated bovine serum albumin (mBSA), which is mechanistically an antigen‐specific and T‐cell‐dependent [32](#all13005-bib-0032){ref-type="ref"} pathology, should be reduced in *Sucnr1* ^*−/−*^ mice, in accordance with our previous observations [16](#all13005-bib-0016){ref-type="ref"}. Unexpectedly, the swelling of the paws from *Sucnr1* ^*−/−*^ mice transferred with K/BxN serum was significantly reduced in comparison with the paw swelling in wt mice (Fig. [3](#all13005-fig-0003){ref-type="fig"}A). Disease amelioration in *Sucnr1* ^*−/−*^ mice correlated with prevention of joint inflammation and with reduction in IL‐1β mRNA expression in popliteal lymph nodes draining the inflamed knees (not shown). Conversely, the results obtained in the AIA model were as predicted. *Sucnr1* ^*−/−*^ mice mounted diminished adaptive responses, and hence, they were less susceptible than wt animals to develop arthritis following challenge with mBSA (Fig. [3](#all13005-fig-0003){ref-type="fig"}B). Together, these results indicate that the potential exacerbation of mast cell activation, which results from deletion of *Sucnr1* gene, does not worsen mast cell‐dependent arthritis. This apparent paradox could be explained by the observation that mast cells are crucial for the initiation of arthritis in the K/BxN serum transfer model but they are dispensable for disease progression, which requires a subsequent recruitment and effector function of macrophages [33](#all13005-bib-0033){ref-type="ref"}.

![*Sucnr1* ^*−/−*^ mice develop milder K/BxN serum and mBSA‐induced arthritis. (A) Inflammatory arthritic response in paws from wt (black circles, *n* = 6) and *Sucnr1* ^*−/−*^ (white circles, *n* = 6) mice after injection of K/BxN serum. Analysis using Welch‐corrected, unpaired Student\'s *t*‐test. Representative Giemsa staining of hind paws from wt (severe edema and inflammation; see asterisks) and *Sucnr1* ^*−/−*^ mice (no edema and reduced inflammation). (B) Inflammatory arthritic response in knees (ratios of antigen challenged *vs* control) from wt (black circles, *n* = 5) and *Sucnr1* ^*−/−*^ (white circles, *n* = 5) mice after mBSA challenge. Analysis using unpaired Student\'s *t*‐test. Representative Giemsa staining of knees from wt (severe inflammation; see asterisks) and *Sucnr1* ^*−/−*^ (reduced inflammation) mice.](ALL-72-444-g003){#all13005-fig-0003}

Classic pathway activation of macrophages is associated with a metabolic switch from oxidative phosphorylation to glycolysis [34](#all13005-bib-0034){ref-type="ref"}, similar to the changes occurring in tumors [35](#all13005-bib-0035){ref-type="ref"}. Succinate dehydrogenase (SDH) catalyzes the conversion of succinate and flavin adenine dinucleotide quinone (FAD) into fumarate plus FAD hydroquinone (FADH~2~), which is coupled to the reduction of ubiquinone in the mitochondrial electron transport chain. Reduced oxygen or increase nutrients, as observed during hypoxia or in obesity, limits the activity of SDH resulting in the accumulation of succinate [36](#all13005-bib-0036){ref-type="ref"}, which is ultimately exported to the cytosol and subsequently to the extracellular environment. Succinate inhibits hypoxia‐inducible factor‐1α (HIF‐1α) prolyl hydroxylase and therefore stabilizes HIF‐1α [37](#all13005-bib-0037){ref-type="ref"}, which in turns enhances IL‐1β production. Recently, Tannahill et al. [38](#all13005-bib-0038){ref-type="ref"} have shown that IL‐1β production by activated macrophages is linked to the accumulation of succinate in the cytoplasm of these cells and we have observed that this mechanism is reinforced by the autocrine and paracrine re‐uptake of secreted succinate by GPR91 expressed on macrophages [39](#all13005-bib-0039){ref-type="ref"}. Thus, although *Sucnr1* ^*−/−*^ mast cells could potentially augment initiation of arthritis, these effects are counteracted by the reduced IL‐1β production by *Sucnr1* ^*−/−*^ macrophages.

The above findings are in line with our previous report, describing succinate as an alarmin [16](#all13005-bib-0016){ref-type="ref"}. The only apparent contradiction was the observed hyperreactivity of *Sucnr1* ^*−/−*^ mast cells, which, although it did not translate into augmented disease, must have a physiological significance. Currently, we can only speculate that mast cells use GPR91 as a homeostatic receptor during their development. Indeed, mast cells from *Sucnr1* ^*−/−*^ mice displayed hypomorphic aspects when compared to equivalent cells from wt mice (Fig. [4](#all13005-fig-0004){ref-type="fig"}A). To search for evidence of the presumed developmental defect, we differentiated mast cells from bone marrow precursors of wt mice in the absence of succinate using serum‐free medium. Such differentiation process was very challenging in comparison with standard protocols performed in FCS‐containing medium. Nevertheless, mast cells differentiated under these conditions and became stimulated in the presence of allergen and specific IgE. We found that the amount of TNF‐α or β‐hexosaminidase secreted by activated mast cells differentiated in the absence of succinate was higher than that produced by mast cells derived from the same precursors differentiated in the presence of 50 μM succinate (Fig. [4](#all13005-fig-0004){ref-type="fig"}B). Thus, the absence of succinate during *in vitro* mast cell development recapitulated *Sucnr1* deficiency. On the other hand, we could not exacerbate cytokine release by wt mast cells differentiated in normal culture medium, which were subsequently devoid of GPR91 signaling by exposure to *Sucnr1*‐specific siRNA (Fig. [4](#all13005-fig-0004){ref-type="fig"}C), further suggesting that the abnormal mast cell response was linked to the development of these cells.

![Mast cells differentiate abnormally in the absence of succinate signaling. (A) Mouse bone marrow‐(BM)‐derived mast cells from *Sucnr1* ^*−/−*^ mice (right) are hypomorphic compared to wt counterparts (left). Toluidine blue staining (40× magnification). (B) TNF‐α and β‐hexosaminidase secretion by wt mast cells differentiated from BM precursors in serum‐free medium (SFM) alone or supplemented with 50 μM succinate (SFM+suc). Cells were stimulated with vehicle (co) or 2 μg/ml IgE plus 0.1 μg/ml DNP‐BSA (IgE/ag). Average results from four (TNF‐α) or seven (β‐hexosaminidase) independent experiments. (C) Expression of *Sucnr1* mRNA by mast cells derived from wt BM after knockdown using specific *Sucnr1* siRNA or scrambled control (left). TNF‐α mRNA expression by control or *Sucnr1* knockeddown mast cells stimulated as indicated in B (right). Average results from four experiments. Analysis using one‐tailed Mann--Whitney *U*‐test or unpaired Student\'s *t*‐test.](ALL-72-444-g004){#all13005-fig-0004}

Here, we have confirmed the role of GPR91 augmenting immune responses, and simultaneously, we have discovered that mast cell development in the absence of GPR91 signaling could lead to an hyperreactive reaction. This effect was apparent in the ACD model but not appreciated in the OVA‐aerosol challenge or in the arthritis models, particularly in the K/BxN model, which is driven by pathogenic autoantibodies. While these results do not eliminate completely the risk of adverse effects mediated by mast cells developing with little GPR91 agonism, they suggest that the maintenance and progression of antibody mediated diseases are not crucially dependent on mast cell function. Of note, the phenotype imposed by genetic deletion of *Sucnr1* is expected to be more penetrant than that enforced by pharmacologic antagonism of GPR91, which could be transient and affecting predominantly DC‐ and macrophage‐mediated enhancement of adaptive effector responses.

Conclusion {#all13005-sec-0015}
==========

This study reports the expression of GPR91 on mouse and human mast cells and reveals a hyperactive behavior of mouse *Sucnr1* ^*−/−*^ mast cells in a mechanistic *in vivo* model of skin inflammation. While such an effect potentially poses a threat for the development of therapeutic antagonists aiming to interfere with adaptive immune responses, subsequent investigations using animal models of asthma and arthritis suggest that the abnormal reactions of *Sucnr1* ^*−/−*^ mast cells are manifestations linked to their development in the absence of succinate signaling and do not exacerbate autoimmune pathology. Overall, our data support the use of GPR91 antagonists for the treatment of autoimmune diseases and particularly for rheumatoid arthritis.
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